MARKET

SRZN

SRZN

Surrozen Inc
NASDAQ
25.21
-0.69
-2.66%
After Hours: 25.21 0 0.00% 16:10 03/13 EDT
OPEN
26.41
PREV CLOSE
25.90
HIGH
27.81
LOW
23.43
VOLUME
164.02K
TURNOVER
--
52 WEEK HIGH
29.60
52 WEEK LOW
5.90
MARKET CAP
216.09M
P/E (TTM)
-1.2761
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SRZN last week (0302-0306)?
Weekly Report · 5d ago
Weekly Report: what happened at SRZN last week (0223-0227)?
Weekly Report · 03/02 09:35
Surrozen to Present at TD Cowen 46th Annual Healthcare Conference
Reuters · 02/25 21:05
Surrozen Reports Inducement Stock Option Grant Under Nasdaq Rule 5635(c)(4)
Reuters · 02/23 21:30
SURROZEN REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 02/23 21:30
Press Release: Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Dow Jones · 02/23 21:30
Weekly Report: what happened at SRZN last week (0216-0220)?
Weekly Report · 02/23 09:34
Surrozen Initiated at Overweight by Cantor Fitzgerald
Dow Jones · 02/19 13:48
More
About SRZN
Surrozen, Inc. is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a focus in ophthalmology. Its product candidates include SZN-8141 for Retinal Diseases, SZN-8143 for Retinal Diseases, SZN-113 for Fuchs’ Endothelial Corneal Dystrophy and Geographic Atrophy, and SZN-413 for Retinal Diseases. SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism which has the potential to provide benefits over treatment with single agents for Diabetic Macular Edema (DME) and neovascular Age Related Macular Degeneration (wet AMD). SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism which may have benefits over single agents for treatment of DME/wet AMD/uveitic macular edema. SZN-413 is a bi-specific antibody, designed using its SWAP technology.

Webull offers Surrozen Inc stock information, including NASDAQ: SRZN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRZN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SRZN stock methods without spending real money on the virtual paper trading platform.